STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter.
Key points
- Continue to STAT+ to read the full story….
- Sign up here to get it delivered to your inbox.
Accountability check: Let’s talk about my “ Alnylam is the next Vertex ” take from the Aug.
Alnylam and Vertex are not direct competitors, but I was intrigued by the possibility that Alnylam’s rapidly accelerating growth — fueled by sales of its blockbuster cardiomyopathy treatment Amvuttra — could push its $60 billion market value equal to or higher than Vertex’s $100 billion market cap in the near future.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 1 article from 1 outlet
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.